ATE251911T1 - Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten - Google Patents

Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten

Info

Publication number
ATE251911T1
ATE251911T1 AT00951595T AT00951595T ATE251911T1 AT E251911 T1 ATE251911 T1 AT E251911T1 AT 00951595 T AT00951595 T AT 00951595T AT 00951595 T AT00951595 T AT 00951595T AT E251911 T1 ATE251911 T1 AT E251911T1
Authority
AT
Austria
Prior art keywords
treatment
skin diseases
containing compositions
inflammatory skin
soluble hla
Prior art date
Application number
AT00951595T
Other languages
English (en)
Inventor
Selim Aractingi
Edgardo Delfino Carosella
Jean Dausset
Daher Iman Khalil
Philippe Moreau
Pascale Paul
Nathalie Rouas-Freiss
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE251911T1 publication Critical patent/ATE251911T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00951595T 1999-06-18 2000-06-16 Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten ATE251911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
PCT/FR2000/001670 WO2000078337A1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Publications (1)

Publication Number Publication Date
ATE251911T1 true ATE251911T1 (de) 2003-11-15

Family

ID=9546968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00951595T ATE251911T1 (de) 1999-06-18 2000-06-16 Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten

Country Status (10)

Country Link
EP (1) EP1189627B1 (de)
JP (1) JP2003508351A (de)
AT (1) ATE251911T1 (de)
CA (1) CA2377519C (de)
DE (1) DE60005952T8 (de)
DK (1) DK1189627T3 (de)
ES (1) ES2206286T3 (de)
FR (1) FR2794977B1 (de)
IL (2) IL147123A0 (de)
WO (1) WO2000078337A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2007011044A1 (ja) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
ATE514726T1 (de) 2006-11-15 2011-07-15 Basf Se Verfahren zur herstellung von polyurethan- weichschaumstoffen
EP2184070A1 (de) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Proteine und pharmazeutische Verwendungen davon
EP2184297A1 (de) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Polypeptide und pharmazeutische Verwendungen davon
EP2264067A1 (de) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 Multimere und pharmazeutische Verwendung davon
CA2764860C (en) 2009-06-25 2018-04-24 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
PL2575881T3 (pl) * 2010-05-28 2018-06-29 Inserm - Institut National De La Santé Et De La Recherche Médicale Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą
KR20250007053A (ko) 2017-05-23 2025-01-13 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 타겟화된 치료학적 면역조절을 위한 mhc 클래스 ib 분자와 펩타이드의 조합
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
AU2020312163A1 (en) * 2019-07-05 2022-02-17 Intellexon Gmbh HLA-H in medicine and diagnostics
US20220023344A1 (en) 2020-06-26 2022-01-27 Crispr Therapeutics Ag Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2213620A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications

Also Published As

Publication number Publication date
FR2794977B1 (fr) 2003-10-31
CA2377519A1 (fr) 2000-12-28
DK1189627T3 (da) 2004-02-16
ES2206286T3 (es) 2004-05-16
IL147123A0 (en) 2002-08-14
CA2377519C (fr) 2011-09-27
WO2000078337A1 (fr) 2000-12-28
DE60005952T2 (de) 2004-07-29
DE60005952T8 (de) 2004-11-04
JP2003508351A (ja) 2003-03-04
EP1189627B1 (de) 2003-10-15
DE60005952D1 (de) 2003-11-20
EP1189627A1 (de) 2002-03-27
FR2794977A1 (fr) 2000-12-22
IL147123A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
ATE308527T1 (de) Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE60042611D1 (de) Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
DE602004016729D1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties